OncoMatch/Clinical Trials/NCT07001709
Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)
Is NCT07001709 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Oxycodone oral capsule 15 mg and Abiraterone Acetate Tablets 500 mg for prostate cancer.
Treatment: Oxycodone oral capsule 15 mg · Abiraterone Acetate Tablets 500 mg — Prostate cancer often leads to bone metastases, which require adequate pain management with opioids such as oxycodone. This study investigates whether abiraterone - a drug used in the treatment of prostate cancer - affects the pharmacokinetics of oxycodone in order to improve pain management.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Excluded: CYP2D6 polymorphism
Excluded: CYP3A4 polymorphism
Prior therapy
Cannot have received: chemotherapy
Exception: Subjects who started their first cycle of chemotherapy during the 2 weeks before the study day
Subjects who started their first cycle of chemotherapy during the 2 weeks before the study day
Cannot have received: opioid substitution therapy (methadone, buprenorphine)
Patients receiving opioid substitution therapy for opioid addiction (e.g. methadone or buprenorphine) and/or suffering from opioid withdrawal
Lab requirements
Kidney function
Moderate-severe renal dysfunction (GFR <60 ml/min/1.73m2) that affects drug metabolism [excluded]
Liver function
No active or symptomatic viral hepatitis or chronic liver disease (e.g. classification with Child-Pugh B, Child-Pugh C)
active or symptomatic viral hepatitis or chronic liver disease (e.g. classification with Child-Pugh B, Child-Pugh C); Moderate-severe renal dysfunction (GFR <60 ml/min/1.73m2) that affects drug metabolism
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify